Tri-county biotech investment firm Westlake Village BioPartners led an $85 million Series A investment in South San Francisco cell therapy and drug discovery startup Arsenal Biosciences. The company will leverage technologies such as CRISPR and a machine learning platform to scale up the process of identifying new drug targets and developing immune cell therapies, starting…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
